ASPH / Aspartyl/asparaginyl beta-hydroxylase · IHC design guide

Design Immunohistochemistry for ASPH

Plan chromogenic IHC on paraffin sections with the IHC-validated antibody at 0.5–1 μg/mL (datasheet PB9478). Use high adipocyte staining and undetected cardiomyocyte staining as tissue references, while accounting for the uncertain tissue-IHC reliability (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for ASPH (IHC for ASPH): expected localisation General cytoplasmic staining (HPA tissue IHC); ER and sarcoplasmic reticulum membranes (UniProt), antibody PB9478, validated IHC image, and IHC protocol steps — Printable **ASPH** IHC protocol sheet — expected localisation General cytoplasmic staining (HPA tissue IHC); ER and sarcoplasmic reticulum membranes (UniProt), antibody PB9478, controls and protocol steps. Open the full ASPH IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

ASPH Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	General cytoplasmic staining (HPA tissue IHC); ER and sarcoplasmic reticulum membranes (UniProt)
	Staining pattern	High adipocyte staining; generally cytoplasmic (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB9478)
	Positive control ⓘ	Adipose tissue+4 more · see all
	Negative control ⓘ	Heart muscle+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PB9478)
	Caveat	Tissue staining has uncertain agreement with RNA (HPA tissue IHC)
	Regulation	Adipose tissue-enhanced RNA (HPA RNA specificity)
	Isoform / epitope	11 isoforms; check whether the epitope is cytoplasmic or luminal (UniProt)

Section 1

Recommended ASPH IHC & IF Protocols

The catalog antibody’s IHC-P protocol is accompanied by published ASPH staining examples from cervical cancer specimens (PMC9373049) and breast tissue sections (PMC7784592).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded Human Mammary Cancer tissue; fixative not specified (datasheet PB9478)
Fixation	Image fixative and duration unreported (datasheet PB9478); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB9478)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9478)
Primary antibody	Rabbit anti-ASPH, 0.5-1μg/ml (datasheet PB9478)
Primary incubation	Overnight at 4 °C (datasheet PB9478)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9478)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	ASPH-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet: PB9478). The cervical cancer protocol reports antigen repair without specifying its method (PMC9373049).

Section 2

What Is the Expected ASPH Staining Pattern?

ASPH is an endoplasmic reticulum (ER) membrane protein with a short cytoplasmic segment and a larger lumenal region (UniProt Q12797 topology). In paraffin-section IHC, expect predominantly cytoplasmic staining, including in adipocytes and colon glandular cells reported as high by HPA (HPA: tissue IHC). Treat the pattern as provisional: HPA rates its tissue IHC profile Uncertain, with medium consistency between staining and RNA data (HPA: tissue IHC reliability).

What am I looking at on my slide?
Cytoplasmic staining in adipocytes or colon glandular cells, with little nuclear signal (HPA: High in both cell types; UniProt Q12797: ER membrane).	This fits the reported tissue pattern and membrane location (HPA: tissue IHC; UniProt Q12797). Judge staining within identified cells, since neighboring cell populations may differ; HPA's overall tissue IHC reliability is Uncertain (HPA: reliability).
Predominantly nuclear staining, or a crisp cell-surface outline without a cytoplasmic component (UniProt Q12797: ER membrane).	That distribution conflicts with the reported ER location (UniProt Q12797; HPA: subcellular ICC-IF). Check morphology and controls before calling it ASPH; nonspecific staining or detection artefact is possible (general IHC practice).
Strong staining in cardiomyocytes or lymph-node germinal center cells (HPA: Not detected in these cell populations).	This disagrees with HPA's cell-level observations and warrants scrutiny for cross-reactivity or endogenous detection activity (HPA: tissue IHC; general IHC practice). HPA's Uncertain reliability means these populations are comparison controls, not definitive biological negatives (HPA: reliability).
Uniform haze across cells, stroma and blank tissue areas, obscuring cell boundaries (general IHC practice).	A field-wide signal cannot establish the reported cell and compartment pattern (HPA: tissue IHC; UniProt Q12797). Review blocking, washes, detection chemistry and a no-primary control for nonspecific background (general IHC practice).
No signal in adipocytes or colon glandular cells that are morphologically present (HPA: High in both cell types).	Investigate assay performance before concluding ASPH is absent: check the IHC-validated antibody, retrieval, detection and control slide (general IHC practice). HPA's High calls guide control choice but do not guarantee every specimen will stain (HPA: tissue IHC; reliability Uncertain).

💡Expected ASPH appearanceCall a result consistent with ASPH when staining is predominantly cytoplasmic in an HPA High cell population, such as adipocytes or colon glandular cells (HPA: tissue IHC; UniProt Q12797: ER membrane); dominant nuclear signal or uniform background is suspect (general IHC practice).

How each factor affects the staining
Membrane topology (UniProt Q12797)	ASPH spans residues 54–74; residues 1–53 are cytoplasmic and 75–758 lumenal (UniProt Q12797 topology). Interpret an antibody's signal in light of its documented epitope, if available; the supplied record gives none.
Cell-level tissue distribution (HPA: tissue IHC)	HPA reports High staining in bronchial respiratory epithelium and cerebellar Purkinje cells, but Not detected in heart cardiomyocytes and skeletal myocytes (HPA: tissue IHC). Identify the scored cell population before comparing tissues.
Isoform context (UniProt Q12797)	UniProt lists 11 isoforms; isoform 1 occurs in all tissues tested, while isoform 8 is mainly expressed in pancreas, heart, brain, kidney and liver (UniProt Q12797). These statements do not establish which isoform an unspecified IHC antibody detects.
Evidence strength (HPA: antibody validation and tissue IHC)	HPA lists HPA059303 IHC as Uncertain and HPA055161 with no IHC status; the overall tissue IHC profile is also Uncertain (HPA: antibody validation; tissue IHC). Use the observed pattern as a guide, not standalone proof of specificity.
IF/ICC Q&A: What location should IF show? (HPA: subcellular ICC-IF)	An ER pattern is expected: HPA reports enhanced ER localisation in ICC-IF, consistent with UniProt's ER membrane annotation (HPA: subcellular ICC-IF; UniProt Q12797). IF/ICC antibody evidence does not establish IHC-P performance (HPA: antibody validation).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Positive-control tissue is blank (HPA: adipocytes and colon glandular cells High).	The selected cells may be absent from the section, or an IHC step may have failed (general IHC practice).	Confirm cell identity and slide integrity; then review the antibody's IHC-P instructions, retrieval and detection controls (general IHC practice).
Signal is mainly nuclear (UniProt Q12797: ER membrane).	The location conflicts with UniProt and HPA's ER assignment; nonspecific staining is possible (UniProt Q12797; HPA: subcellular ICC-IF; general IHC practice).	Compare a no-primary control and a known HPA High cell population; reassess the antibody's IHC validation (general IHC practice; HPA: tissue IHC).
Cardiomyocytes stain strongly (HPA: heart cardiomyocytes Not detected).	Cross-reactivity or endogenous chromogenic activity may mimic a positive result (general IHC practice). HPA's tissue IHC reliability is Uncertain (HPA: reliability).	Check no-primary and detection controls, then compare compartment and intensity with an HPA High cell population (general IHC practice; HPA: tissue IHC).
Diffuse brown background hides cell boundaries (general IHC practice).	Nonspecific binding, residual endogenous enzyme activity or excess chromogen development may contribute (general IHC practice).	Inspect no-primary and detection controls; review blocking, washing and chromogen development under the established IHC workflow (general IHC practice).
High and low cell populations look equally intense (HPA: tissue IHC).	Background or signal saturation may obscure the reported differences; HPA also rates its profile Uncertain (general IHC practice; HPA: reliability).	Score identified cell populations separately and assess controls before interpreting relative intensity (general IHC practice).
IF shows an ER pattern but paraffin IHC is negative (HPA: subcellular ICC-IF).	HPA's ICC-IF localisation and its IHC validation are separate observations; the supplied evidence does not establish a target-specific fixation effect (HPA: antibody validation).	Evaluate IHC-P controls and the antibody's documented IHC-P conditions before interpreting the negative section (general IHC practice).

Source: UniProt Q12797 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing ASPH staining

IHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in paraffin-embedded section of Human Mammary Cancer Tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-ASPH Antibody (PB9478) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9478 · IHCIHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in paraffin-embedded section of Human Mammary Cancer Tissue. Heat

IHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in immunocytochemical section of A549 cell. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 1μg/ml rabbit anti-ASPH Antibody ( PB9478) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9478 · IHCIHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in immunocytochemical section of A549 cell. Enzyme antigen retriev

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/cerebral+cortex#imid_16393615

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/colon#imid_16411337

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/liver#imid_16411463

HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/pancreas#imid_16411395

HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA055161; green = ASPH, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for ASPH IHC & IF

🧪Run adipose tissue first; its adipocytes should stain strongly (HPA: High in adipocytes). Use lymph node germinal center cells as the negative tissue (HPA: Not detected in germinal center cells); on the adipose slide, treat nonadipocyte cells as internal negatives only where they lack specific staining (HPA: positive designation is for adipocytes).

Positive control tissue: Adipose tissue (Adipocytes, HPA High)

Negative control tissue: Heart muscle (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ASPH in HeLa, U2OS, A-549, BJ [Human fibroblast], with annotated localisation: Endoplasmic reticulum (enhanced) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control and a matched rabbit IgG isotype control (caption: rabbit anti-ASPH; standard IHC practice). Confirm specificity with an ASPH knockout specimen or cell pellet, and block endogenous peroxidase while checking the adipose control for background signal (standard IHC practice).

⚠️Feasibility: The selected PB9478 paraffin-section caption does not report a fixative, and no target-specific fixation window or fixation effect is reported (caption: fixative not stated). Heat retrieval in citrate buffer at pH 6 for 20 minutes is documented, but whether retrieval is required has not been established (caption: heat-mediated antigen retrieval); neither frozen sections nor IF can be judged easier from the supplied evidence. In paraffin adipose sections, lipid extraction leaves adipocyte cytoplasm as a thin rim, so assess staining at that rim rather than within the empty lipid space (standard histology practice).

HPA tissue IHC evidence for ASPH

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	High	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Breast	Adipocytes	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Caudate	Glial cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Heart muscle	Cardiomyocytes	Not detected	Protein (IHC)	HPA →
Liver	Cholangiocytes	Not detected	Protein (IHC)	HPA →
Lymph node	Germinal center cells	Not detected	Protein (IHC)	HPA →
Parathyroid gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Skeletal muscle	Myocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced ASPH IHC Tips

Troubleshoot ASPH staining in paraffin sections by checking retrieval, cellular pattern and controls before interpreting chromogenic signal.

Which retrieval condition should I start with for ASPH IHC?

Start with heat-mediated citrate retrieval at pH 6 for 20 minutes (PB9478 IHC caption). The selected paraffin-section image used this treatment before a 10% goat-serum block and 1 µg/mL antibody incubation overnight at 4°C (PB9478 IHC caption). If staining is weak, check heating uniformity, section adherence and cooling before changing retrieval conditions (standard IHC practice). ASPH spans the ER membrane, with cytoplasmic residues 1–53 and lumenal residues 75–758, so the unknown antibody epitope matters when assessing accessibility (UniProt Q12797 topology). Compare each retrieval adjustment with the starting condition on matched sections and assess cellular pattern alongside intensity (standard IHC practice).

Can the published paraffin staining tell me which fixation preserves ASPH?

The selected ASPH image identifies a paraffin-embedded section but does not state its fixative, so target-specific fixation sensitivity is unknown (PB9478 IHC caption). Record the specimen fixative and fixation duration, then keep processing consistent across sections that will be compared (standard IHC practice). If signal varies, compare matched material processed under documented conditions while holding citrate retrieval at pH 6 for 20 minutes constant (PB9478 IHC caption; standard IHC practice). Include a staining control in each run and inspect tissue preservation before assigning a weak result to antigen loss (standard IHC practice). The reported tissue staining pattern cannot establish an optimal fixative or fixation time for this antibody (HPA tissue IHC; PB9478 IHC caption).

Where should convincing ASPH staining appear in a paraffin section?

Expect a predominantly cytoplasmic pattern compatible with intracellular membranes: ASPH is assigned to the endoplasmic and sarcoplasmic reticulum membranes, and HPA reports general cytoplasmic staining (UniProt Q12797 localisation; HPA tissue IHC). Examine whether signal follows intact cells rather than section edges, debris or broad extracellular deposits (standard IHC practice). HPA reports high staining in adipocytes in adipose tissue and breast, but its tissue-IHC reliability is marked uncertain (HPA tissue IHC). A strong nuclear-only or diffuse extracellular pattern warrants review of controls and morphology before being called ASPH (UniProt Q12797 localisation; standard IHC practice). Compare the same cell compartment across specimens when judging differences in intensity (standard IHC practice).

Could ASPH isoforms or epitope location explain discordant IHC results?

ASPH has 11 listed isoforms, and the supplied antibody caption does not identify its epitope or establish which isoforms it detects (UniProt Q12797 isoforms; PB9478 IHC caption). Check the antibody's documented immunogen or epitope before treating staining intensity as total ASPH abundance (standard IHC practice). The full-length protein has a membrane segment at residues 54–74, with residues 1–53 cytoplasmic and 75–758 lumenal (UniProt Q12797 topology). UniProt lists glycosylation sites at residues 64, 452 and 706; epitope proximity to a modification would need direct evidence to explain altered staining (UniProt Q12797 glycosylation). Isoform 8 has a reported tissue distribution distinct from broadly detected isoform 1, so record the tested isoform when comparing studies (UniProt Q12797 tissue specificity).

How should I check an ASPH signal in a multiplex IF experiment?

For the separate IF/ICC workflow, pair ASPH with a cell-identity marker appropriate to the specimen; adipocytes are one high-staining cell population reported by HPA (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and consider a far-red channel when tissue autofluorescence interferes with shorter wavelengths (standard IF practice). Acquire unstained and single-label controls to distinguish autofluorescence and spectral bleed-through from colocalisation (standard IF practice). Plan permeabilisation around the antibody's verified epitope: ASPH residues 1–53 face the cytoplasm, whereas residues 75–758 face the ER lumen (UniProt Q12797 topology). The supplied IHC caption does not establish IF fixation, permeabilisation or antibody performance; validate those conditions directly for IF (PB9478 IHC caption; standard IF practice).

What should I check when ASPH DAB staining looks diffuse?

First inspect a no-primary control and the distribution of signal in intact tissue; widespread DAB deposition can reflect detection background (standard IHC practice). The selected image used 10% goat serum, a biotinylated secondary antibody, a streptavidin–biotin complex and DAB (PB9478 IHC caption). Check blocking, washing and secondary-antibody specificity, and consider endogenous biotin when using that detection chemistry (standard IHC practice). Include a peroxidase block before DAB development and check for residual endogenous peroxidase activity; these are general chromogenic-IHC controls, not demonstrated ASPH-specific requirements (standard IHC practice). If background remains high, titrate primary antibody around the caption's 1 µg/mL condition while retaining a matched control section (PB9478 IHC caption; standard IHC practice).

How can I score ASPH IHC without mixing cell composition and staining strength? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and cytoplasmic scoring compartment before reviewing outcomes, consistent with the reported ASPH tissue pattern (HPA tissue IHC; standard IHC practice). An H-score combines the percentages of cells at intensity grades 0–3 and spans 0–300 (standard IHC practice). Report the percentage of positive cells alongside the score so that changes in prevalence and intensity remain distinguishable (standard IHC practice). For spatial analyses, express positive-cell density per mm² of viable annotated tissue and state which cells enter the denominator (standard IHC practice). Keep retrieval, detection and scoring thresholds consistent across compared sections, and account for differences in cell composition (standard IHC practice).

How do I separate genuine ASPH staining from section artefacts?

Judge a putative positive by its cellular location, morphology and controls: ASPH is associated with ER and sarcoplasmic reticulum membranes, while HPA describes general cytoplasmic staining (UniProt Q12797 localisation; HPA tissue IHC). Check that signal belongs to the intended cells; HPA reports high adipocyte staining in adipose tissue but no detected staining in cardiomyocytes (HPA tissue IHC). Treat edge accentuation and staining over necrotic material as suspect until they are resolved with morphology and matched controls (standard IHC practice). A no-primary control helps identify detection background, including endogenous enzyme effects in chromogenic workflows (standard IHC practice). Interpret tissue differences cautiously because HPA assigns its ASPH tissue-IHC evidence uncertain reliability (HPA tissue IHC).

Boster reagents

Best ASPH / Aspartyl/asparaginyl beta-hydroxylase IHC Antibodies

PB9478 has real ASPH IHC data from a human paraffin-embedded mammary cancer section (PB9478 image caption). Human, mouse and rat reactivity is listed (catalog reactivity); no IF figure is supplied (catalog IF images).

Real IHC data

Anti-Aspartate beta hydroxylase/ASPH Antibody ®

Cat # PB9478

View product →

PB9478 will render with an IHC image from a human paraffin-embedded mammary cancer section (PB9478 IHC image caption). Its applications include IHC and ICC, and a separate caption documents A549 cells; listed reactivity is human, mouse and rat (catalog applications; PB9478 ICC image caption; catalog reactivity).

Which to pick: For tissue IHC, choose PB9478: its image documents a human paraffin-embedded section with citrate retrieval at pH 6 for 20 minutes; the fixative is unreported (PB9478 IHC image caption). For ICC, PB9478 is listed and shown with A549 cells, but no IF figure is supplied (catalog applications; PB9478 ICC image caption; catalog IF images). For cross-species work, PB9478 lists human, mouse and rat reactivity, while its tissue IHC image documents human tissue only (catalog reactivity; PB9478 IHC image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q12797 (ASPH_HUMAN, Aspartyl/asparaginyl beta-hydroxylase).
Human Protein Atlas. ASPH tissue IHC expression (reliability: Uncertain).
Human Protein Atlas. ASPH subcellular location (ICC-IF): Localized to the endoplasmic reticulum..
Human Protein Atlas. ASPH antibody validation summary (2 antibodies).
Aspartate β-hydroxylase Regulates Expression of Ly6 Genes. Journal of Cancer 2024 — PMC10861829.
Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. Journal of Cancer 2024 — PMC11134442.
Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics. Frontiers in oncology 2022 — PMC9373049.
Characterization of the Relationship Between the Expression of Aspartate β-Hydroxylase and the Pathological Characteristics of Breast Cancer. Medical science monitor : international medical journal of experimental and clinical research 2020 — PMC7784592.
PubMed PMID:7821814 — UniProt-cited evidence.
PubMed PMID:8823296 — UniProt-cited evidence.
PubMed PMID:10974562 — UniProt-cited evidence.